The company plans to initiate the next stage of development during the third quarter of this year. This expanded study will incorporate existing research sites in Australia while integrating new clinical locations across the United States and Europe. Chief Executive Officer Gene Mack described the authorization as a validation of the extensive preclinical and clinical data amassed to date, marking a critical transition point for the biotechnology firm’s lead pipeline asset.